New class of antibiotics discovered – and why there may be more to come

January 12, 2015 by Angelika Gründling, The Conversation
Food for drug-resistant bacteria. Credit: AthanArk, CC BY-NC-ND

The rise of bacteria that are resistant to antibiotics is a growing worry and threatens to put healthcare back to the early 20th century. Such resistance to drugs was inevitable, because bacteria evolve and learn to defend themselves. But we are worried now because new classes of antibiotics aren't being found.

Now we may have to worry a little less. Researchers have discovered a new drug, called teixobactin, which marks the launch of a new class of . Better still, they show that even highly sensitive bacteria may not easily develop to this new antibiotic.

Beyond the discovery of the drug, their study published in Nature is remarkable for another reason. The technology developed by these could herald the discovery of many new classes of antibiotics.

How iChip works

In a single scoop of soil, bacteria and fungi number in the millions. They also come in thousands of varieties, and survive by fighting each other. We know this because for the past century, several newly discovered antibiotics have been found by isolating them from the bacteria and fungi that produce them to defend their own lives.

The trouble, however, is that only about 1% of the microbes in the soil (or sea water) can be reliably grown under lab conditions. This means that so far we have not been able to study the remaining 99%, which are bound to produce antibiotics unknown to us.

iChip technology at work. Credit: Losee L. Ling et al / Nature

This is the problem Kim Lewis and Slava Epstein at Northeastern University in Boston and colleagues have been busy trying to solve. After more than a decade of work, they have a solution in the iChip technology.

To make it work, a sample of soil is diluted and then poured on the iChip, which consists of hundreds of small holes. Because of the dilution, it is hoped that only one microbe is caught in each hole.

The iChip is then covered with membranes on both sides and put back into the soil sample. The membranes contains pores that are only large enough for chemical nutrients to flow in but small enough to block the movement of any bacteria. This means the single bacteria in each of the holes in the iChip can consume all the nutrients it would naturally find in the environment and multiply, but not be contaminated with other bacteria in the soil.

Remarkably, it has been shown that this method can help nearly one in two bacteria to start growing in the iChip cells. Better still, three-quarters of the iChip bacteria can then be transferred to and grown in lab solutions. Quite the improvement from the 1% that could be previously grown in labs.

Why this transition through the iChip allows previously incapable bacteria to grow in lab solutions is not clear, but it may have to do with mutations gained by the bacteria during the process. And this step is crucial because it might help to overcome a huge barrier that was stopping the development of new antibiotics – growing bacteria under lab conditions to study and isolate the antibiotics they produce.

From soil to pills

Because Lewis was able to grow some of the to a large scale, he could isolate the antibiotics they produced to test if any of them were new. One bacteria, called Eleftheria terrae, was found to produce the best antibiotic candidate, which became teixobactin.

An analysis of teixobactin reveals that it attacks an essential precursor required for the production of cell walls in bacteria. Although it is not the first antibiotic to attack cell walls, it is able to do so quite effectively, albeit in petri-dishes and in mice.

But teixobactin attacks only Gram-positive bacteria, which have a thick cell wall but lack an outer membrane and cause diseases such as diphtheria and tetanus. Gram-negative bacteria are further protected by an outer membrane and this makes them insensitive to the antibiotic. So infections with Gram-negative bacteria often even more problematic to treat when it comes to drug-resistance and will need to be attacked with a different antibitoic.

The chances of teixobactin becoming a drug suitable for humans is currently hard to estimate. But the odds of a drug candidates that works in mice making it through the clinical trials process is in general slim. And if Teixobactin does not make it, it could be chemically modified to make it work in humans. Crucially, though, Lewis's technology has the potential to lead to the of other new classes of antibiotics.

The greatest developments in science are often not the discoveries but the developments that enable them. So while teixobactin is certainly a remarkable achievement, the new method to grow soil in labs is an equally important contribution that Lewis and his team have made.

Explore further: New approach sees breakthrough in antibiotics research

Related Stories

New approach sees breakthrough in antibiotics research

January 7, 2015
Scientists using a revolutionary approach have devised an antibiotic that may offset the mounting problem of drug resistance for decades, they said on Wednesday.

New method of finding drugs more important than new antibiotic itself

January 12, 2015
It was big news this week when Nature published the discovery of a new antibiotic, teixobactin. Teixobactin, which kills bacteria by a different pathway than other antibiotics, represented the first new class of antibiotics ...

Antibiotic resistance is a gut reaction

December 16, 2014
Scientists from the Institute of Food Research and the University of East Anglia have discovered how certain gut bacteria can protect themselves and others in the gut from antibiotics.

Study shows manure from cows not given antibiotics still causes increase in resistant bacteria in soil

October 7, 2014
(Phys.org) —A team of researchers working out of Yale University has found that soil treated with cow manure from cows that never received antibiotics, still had more resistant bacteria in it than soil treated with nonorganic ...

Recommended for you

Researchers find infectious prions in Creutzfeldt-Jakob disease patient skin

November 22, 2017
Creutzfeldt-Jakob disease (CJD)—the human equivalent of mad cow disease—is caused by rogue, misfolded protein aggregates termed prions, which are infectious and cause fatal damages in the patient's brain. CJD patients ...

Study reveals new mechanisms of cell death in neurodegenerative disorders

November 22, 2017
Researchers at King's College London have discovered new mechanisms of cell death, which may be involved in debilitating neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Surprising roles for muscle in tissue regeneration, study finds

November 22, 2017
A team of researchers at Whitehead has illuminated an important role for different subtypes of muscle cells in orchestrating the process of tissue regeneration. In a paper published in the November 22 issue of Nature, they ...

How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis

November 21, 2017
Drug designers working on therapeutics against multiple sclerosis should focus on blocking two distinct ways rogue immune cells attack healthy neurons, according to a new study in the journal Cell Reports.

New simple test could help cystic fibrosis patients find best treatment

November 21, 2017
Several cutting-edge treatments have become available in recent years to correct the debilitating chronic lung congestion associated with cystic fibrosis. While the new drugs are life-changing for some patients, they do not ...

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.